Comparison of survival outcomes for people with HR+/HER2- metastatic breast cancer who received palbociclib, ribociclib, or abemaciclib with an aromatase inhibitor: a plain language summary.

Authors

Hope S Rugo, Rachel M Layman, Filipa Lynce, Xianchen Liu, Benjamin Li, Lynn McRoy, Aaron B Cohen, Melissa Estevez, Giuseppe Curigliano, Adam Brufsky

Published in

Future oncology (London, England). Pages 1-11. Jun 21, 2026. Epub Jun 21, 2026.

PMID:
42324670
Bibliographic data and abstract were imported from PubMed on 22 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.